In Warning Letter, FDA Says ParagonDx ASR Probes for Warfarin Sensitivity Require Premarket Approval
April 07, 2010
In Warning Letter, FDA Says ParagonDx ASR Probes for Warfarin Sensitivity Require Premarket Approval
According to the agency, ParagonDx's ASR probes for gauging the presence of CYP2C9*2, CYP2C9*3, VKORC1 1173, VKORC1 3730 variants "are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or are intended to affect the structure or function of the body."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- With Top-line Deep-C Trial Data, Exact Sciences Gears Up for FDA and CMS Submissions for Cologuard
April 24, 2013 / Pharmacogenomics Reporter - Exact Sciences Discusses Benefits of Taking Cologuard through FDA/CMS Parallel Review Pilot
April 3, 2013 / Pharmacogenomics Reporter - Palmetto's Initial MDx Pricing Disappoints Industry; Raises Concerns about Business Impact
February 6, 2013 / Pharmacogenomics Reporter - Study Finds KRAS Testing in Metastatic CRC Saves Money, but Questions Value of EGFR Inhibitors
November 28, 2012 / Pharmacogenomics Reporter - Policy Experts Say Myriad's Proprietary Variant Database Sets Bad Precedent for Personalized Medicine
November 2, 2012 / Pharmacogenomics Reporter